Want to see AU:IXC full AI Analyst Report?
Top Page
Invex Therapeutics Ltd.
(Sydney:IXC)
Select Model
Select Model
Rating:48Neutral
Price Target:
AU$0.11
▼(-5.00% Downside)
Action:Reiterated
Date:09/15/26
The score is held down primarily by weak financial performance (unstable/absent revenue, ongoing losses, and continued cash burn, despite no debt). Technical indicators are broadly neutral and provide only modest support, while valuation is constrained by negative earnings and no dividend yield data.
Positive Factors
Debt-Free Balance Sheet
A debt-free balance sheet reduces interest obligations and refinancing exposure, giving Invex greater flexibility while it advances its development program. This provides a financial buffer against volatility and preserves more strategic options than a similarly loss-making company carrying material leverage.
Negative Factors
Unstable Revenue and Ongoing Losses
The absence of sustained revenue and continued operating and net losses indicate that the business has not yet demonstrated commercial traction. This weak earnings foundation limits internally funded growth and leaves future results highly dependent on successful development and eventual commercialization.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt-Free Balance Sheet
A debt-free balance sheet reduces interest obligations and refinancing exposure, giving Invex greater flexibility while it advances its development program. This provides a financial buffer against volatility and preserves more strategic options than a similarly loss-making company carrying material leverage.
Read all positive factors
Invex Therapeutics Ltd. (IXC) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$8.27M
Dividend Yield248.4%
Average Volume (3M)31.29K
Price to Earnings (P/E)―
Beta (1Y)0.24
Revenue GrowthN/A
EPS Growth-185.71%
CountryAU
Employees4
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.02
Shares Outstanding75,153,850
10 Day Avg. Volume13,333
30 Day Avg. Volume31,289
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)1.73
Price to Sales (P/S)0.00
P/FCF Ratio-4.98
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Invex Therapeutics Ltd. Business Overview & Revenue Model
Company Description
Invex Therapeutics Ltd is an Australian biopharmaceutical company dedicated to researching and developing innovative treatments for various neurological disorders. Their primary focus is Exenatide, a promising therapeutic agent aimed at neurologic...
Invex Therapeutics Ltd. Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
24
Negative
| Breakdown | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 229.08K | 1.21M | 459.08K | 182.25K |
| Gross Profit | 0.00 | 229.08K | 1.21M | 459.08K | 182.25K |
| EBITDA | -1.54M | 0.00 | -720.00K | -8.21M | -4.14M |
| Net Income | -1.35M | -476.87K | -1.64M | -7.75M | -3.95M |
Balance Sheet | |||||
| Total Assets | 4.06M | 5.47M | 6.12M | 22.80M | 29.49M |
| Cash, Cash Equivalents and Short-Term Investments | 4.02M | 5.38M | 6.03M | 22.47M | 29.34M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 153.47K | 220.59K | 431.63K | 1.57M | 1.00M |
| Stockholders Equity | 3.91M | 5.25M | 5.69M | 21.23M | 28.48M |
Cash Flow | |||||
| Free Cash Flow | -1.36M | -652.57K | -2.44M | -6.87M | -3.38M |
| Operating Cash Flow | -1.36M | -652.57K | -2.44M | -6.87M | -3.38M |
| Investing Cash Flow | -2.50M | 0.00 | 0.00 | 0.00 | 0.00 |
| Financing Cash Flow | 0.00 | 0.00 | -14.00M | 0.00 | 0.00 |
Invex Therapeutics Ltd. Technical Analysis
Negative
0.12
Price Trends
0.12
Negative
0.11
Negative
0.11
Negative
Market Momentum
>-0.01
Positive
45.79
Neutral
50.00
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:IXC, the sentiment is Negative. The current price of 0.12 is above the 20-day moving average (MA) of 0.11, above the 50-day MA of 0.12, and above the 200-day MA of 0.11, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 45.79 is Neutral, neither overbought nor oversold. The STOCH value of 50.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:IXC.
Invex Therapeutics Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | AU$14.72M | -1.98 | -247.44% | ― | -4.24% | 33.39% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | AU$8.27M | -6.11 | -31.98% | 248.40% | ― | -185.71% | |
46 Neutral | AU$5.81M | -7.14 | -45.29% | 9.09% | 290.25% | 92.05% | |
43 Neutral | AU$49.71M | -0.56 | -118.74% | ― | 499.47% | 31.20% | |
43 Neutral | AU$5.14M | -0.96 | -52.04% | ― | 32.22% | -26.53% | |
42 Neutral | AU$17.98M | -13.21 | -29.22% | ― | ― | 81.00% |
* Healthcare Sector Average
AU:IXC
Invex Therapeutics Ltd.
0.11
-0.04
-26.67%
AU:ACR
Acrux
0.01
>-0.01
-28.57%
AU:TRP
Tissue Repair Ltd
0.09
-0.20
-70.69%
AU:CMB
Regeneus Ltd.
0.52
0.00
0.00%
AU:AGN
Argenica Therapeutics Ltd
0.14
-0.11
-45.10%
AU:BOT
Botanix Pharmaceuticals Limited
0.02
-0.14
-87.74%
Invex Therapeutics Ltd. Corporate Events
Invex Therapeutics Posts Deeper Loss but Strengthens Asset Backing in 2026
Aug 31, 2026
Invex Therapeutics Ltd reported a significantly wider loss for the year ended 30 June 2026, with loss after tax attributable to members rising to $1.35 million as other income fell sharply compared with the previous year. Despite the deeper losses...
Invex Boosts Alzheimer’s Research Spend as Expanded GLP-1 Study Advances
Jul 23, 2026
Invex Therapeutics has expanded its preclinical research collaboration with Tessara Therapeutics, testing Exenatide and other GLP-1 receptor agonists, including combination regimens, in Tessara’s human iPSC-derived three-dimensional Alzheime...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.